
BioCardia, Inc. (NASDAQ:BCDA – Free Report) – Stock analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for shares of BioCardia in a report released on Friday, November 13th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.63) for the year, up from their prior forecast of ($0.71). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for BioCardia’s current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for BioCardia’s Q4 2026 earnings at ($0.17) EPS, FY2027 earnings at ($0.48) EPS and FY2028 earnings at ($0.28) EPS.
Several other equities research analysts also recently weighed in on the company. Zacks Research raised BioCardia from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Wall Street Zen upgraded shares of BioCardia from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $25.00.
Get Our Latest Research Report on BCDA
BioCardia Price Performance
Shares of NASDAQ:BCDA opened at $0.79 on Tuesday. The business’s 50-day moving average is $1.00 and its 200 day moving average is $1.05. BioCardia has a 1 year low of $0.66 and a 1 year high of $1.80. The firm has a market capitalization of $11.96 million, a P/E ratio of -1.52 and a beta of 0.69.
BioCardia (NASDAQ:BCDA – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01.
Hedge Funds Weigh In On BioCardia
An institutional investor recently raised its position in BioCardia stock. StoneX Group Inc. lifted its position in BioCardia, Inc. (NASDAQ:BCDA – Free Report) by 67.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 33,445 shares of the company’s stock after acquiring an additional 13,425 shares during the period. StoneX Group Inc. owned 0.22% of BioCardia worth $33,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 20.57% of the company’s stock.
About BioCardia
BioCardia, Inc. is a biotechnology company developing regenerative therapies for cardiovascular and pulmonary diseases. Its work centers on cell-based treatments intended to support the repair or function of damaged tissues. The company’s investigational programs include CardiAMP, an autologous cell therapy developed using a patient’s own bone marrow cells, and CardiALLO, an allogeneic therapy using donor cells. BioCardia also develops catheter-based systems, including its Helix device, to deliver biologic treatments to the heart.
Featured Stories
- Five stocks we like better than BioCardia
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
